# **PATIENT**

NAME: **TEST2 PATIENT** GENDER: **Male**DATE OF BIRTH: **02/23/1999** AGE: **22** 

ACCESSION ID: 2108060411

SPECIMEN COLLECTION TIME: 08-05-2021 18:08 SPECIMEN RECEIVED TIME: 08-06-2021 12:09 FINAL REPORT TIME: 08-06-2021 18:11

FASTING: FASTING

# **PROVIDER**

PRACTICE NAME: Vibrant IT4 Practice
PROVIDER NAME: Demo Client, DDD (999994)
ADDRESS: TEST STREET, TEST CITY, KY- 42437.

The comments in this report are meant only for informational purposes and do not constitute medical advice. Please consult your physician for any medication, treatment or life style management.

# **Vibrant Wellness Test Index**





#### PATIENT

NAME: **TEST2 PATIENT** GENDER: **Male** DATE OF BIRTH: **02/23/1999** AGE: **22** 

ACCESSION ID: 2108060411

SPECIMEN COLLECTION TIME: 08-05-2021 18:08
SPECIMEN RECEIVED TIME: 08-06-2021 12:09
FINAL REPORT TIME: 08-06-2021 18:11

FASTING: FASTING

#### **PROVIDER**

PRACTICE NAME: Vibrant IT4 Practice
PROVIDER NAME: Demo Client, DDD (999994)
ADDRESS: TEST STREET, TEST CITY, KY- 42437.

**Vibrant Wellness** is pleased to present to you **Gut Zoomer** testing to help you make healthy lifestyle choices in consultation with your physician and dietitian. It is intended to be used as a tool to encourage general healthy lifestyle choices.

**Gut Zoomer 3.0** is a health analytics tool based on the gut microbiome which provides potential risks for intestinal permeability, cardiovascular, metabolic, neurological, intestinal, autoimmune, liver, hormonal, and nutritional health conditions. Additionally it has panels for detection of gut pathogens and digestive markers. It is intended to be used to improve functions associated with a general state of health, and where it is well understood as well as accepted that healthy lifestyle choices may play an important role in these health outcomes.

Interpretation of Report: The following terminologies are used consistently in the report and are explained below.

**Gut Diversity** is an indicator for the amount of individual bacteria from each of the bacterial species present in your gut microbiome. There are two indices calculated including Shannon's Index (Scale 0-3) and Simpson's Index (Scale 0-1). For both calculations, higher index value represents increased diversity of species. While Shannon's is a better indicator of 'Richness' of the diversity, Simpson's is a better indicator of 'Evenness'. For Shannon's Index, the reference range for high diversity is >= 2.5 units, for moderate diversity is 1.5 - 2.5 units and for low diversity is <= 1.5 units. For Simpson's Index, the reference range for high diversity is >= 0.75 units, for moderate diversity is 0.5 - 0.75 units and for low diversity is <= 0.5 units. The calculated Index values are surrounded with a risk indicator (Green – high diversity, Yellow – moderate diversity, and Red – low diversity).

Gut Phyla distribution is displayed in a pie chart with each pie representing the % of individual phyla tested.

Key Ratios are calculated and displayed comprising of F/B (Firmicutes to Bacteroidetes ratio) and P/B (Prevotella to Bacteroides ratio), along with the corresponding risk indicator.

**Gut Commensal** bacteria is represented using relative abundance values. **Relative abundance** is the percent composition of an organism of a particular kind relative to the total number of organisms in your gut microbiome. The abundance of individual bacterial phylum/family/genus/species is calculated by comparing the relative abundance to the healthy reference range. Reference ranges have been established using results from 192 healthy individuals.

In some cases, a high abundance is potentially associated with an increased risk for a condition and in some cases a low abundance is potentially associated with an increased risk for a condition. The abundance is always mentioned in the report along with the potential associated risks, however, it is applicable only when indicated in RED. Associated probiotic tests are displayed in each panel with suggestions based on potential associated risks.

Ratings are calculated based on the impact factor, citations, and study population of the references which correlate the bacterial organism with the associated conditions. It is indicated with a star based system (1 star – 5 stars) with 5 stars indicating the best correlation of the bacteria with the potential associated risk. The impact factor of the journal in which the reference is published is the number of citations received by articles published in that journal during the two preceding years, divided by the total number of articles published in that journal during the two preceding years. Study population includes the number of samples tested along with gender, age, and ethnicity of the population.

**Gut Pathogens** comprising of pathogen ic bacteria, parasites, virus, and fungi are indicated as DETECTED or NOT DETECTED along with the levels in respective units. Worm and antibiotic resistance gene testing is displayed as DETECTED or NOT DETECTED based on the test result.

Inflammation and Digestive Insufficiency markers are displayed along with a risk indicator and the corresponding reference range for each test calculated using results from 192 healthy individuals. All test results are displayed with risk indicator and abundance direction as applicable. (Red – High Risk, Yellow – Moderate Risk and Green – Low Risk).

Vibrant Wellness is a personalized health analytics company founded out of our passion to serve patients and providers. The Vibrant Wellness platform provides tools for you to track and analyze your general wellness profile. All testing offered by Vibrant Wellness is performed at a CLIA approved lab testing facility and licensed by California Department of Public Health.

Please Note - Consider all supplements in relation to medical history and symptoms. Not all recommended supplements are appropriate in all individual cases. It is important that you discuss any modifications to your diet, exercise and nutritional supplementation with your physician before making any changes. Pediatric ranges have not been established for these tests.

DATE OF SERVICE:



**TEST2 PATIENT** 

**FULL NAME:** 


Shannon's Index
Scale: 0 - 3
Ref Range: ≥2.5
Prev value: 1.2

NOTE:


0.74

Simpson's Index
Scale: 0 - 1
Ref Range: ≥0.75
Prev value: 0.57

Higher value, Higher Diversity



ACCESSION ID: 2108060411



08-05-2021 18:08

Consider these supplements in relation to medical history and symptoms. Not all recommended supplements are appropriate in all individual cases. Consult a knowledgeable healthcare provider before taking any supplemental nutrients or probiotics.

GUT COMME	NS/	ALS							•	Low	• Mo	derate	• Hig	h
TEST NAME			CURF	RENT		PREV	TEST NAME			CURF	RENT		PI	REV
INTESTINAL PERMEABILITY	0.0	2.0	3.9	6.0	• 2.0	3.4	SIBO	0.0	2.0	3,9	6.0	• 1.7	•	2.4
CARDIOVASCULAR HEALTH	0.0	2.0	3.9	6.0	• 1.4	1.0	AUTOIMMUNE HEALTH	0.0	2.0	3.9	6.0	• 1.2	•	2.3
METABOLIC HEALTH	0.0	2.0	3.9	6.0	2.2	2.3	NUTRITION	0.0	2.0	3.9	6.0	• 1.3	•	2.0
NEUROLOGICAL HEALTH	0.0	2.0	3.9	6.0	2.3	• 2.0	LIVER HEALTH	0.0	2.0	3.9	6.0	• 1.9	•	2.1
BD	0.0	2.0	3.9	6.0	1.5	• 1.7	IBS	0.0	2.0	3.9	6.0	• 1.1	•	1.3
HORMONES	0.0	2.0	3.0	6.0	• 0.9	1.0								

#### **COMMENTS:**

Commensal bacteria in imbalance are Butyrivibrio, Streptococcus species, Enterococcus species, Atopobium, Roseburia intestinalis, Staphylococcaceae, Oscillospira, Clostridium hathewayi, Clostridium symbiosum, Lactobacillus paracasei, Propionibacterium freudenreichii, Clotridiales Incertae Sedis IV, Desulfovibrio, Bacteroides vulgatus, Prevotella, Methanobrevibacter, Leuconostoc, Desulfovibrio piger, Saccharomyces boulardii, Lactobacillus salivarius, Escherichia coli Nissle, Bifidobacterium infantis.

Suggested probiotics include: Lactobacillus paracasei, Saccharomyces boulardii, Lactobacillus salivarius, Escherichia coli Nissle, Bifidobacterium infantis.

Suggested supplements include: Arabin ogalactan, Inulin, Berberine, Origanum vulgare, Wormwood oil, Lemon balm oil, Barberry root extract, Omega-3 fatty acids, vitamin D, isoflavone, Taurine, Chitin-Glucan, peptidase, Whey protein concentrate, Watercress, Green tea catechins, protease, amyloglucosidase, beta-glucanase, alpha-galactoidase, lipase, amylases, glycine, Pantothenic Acid, riboflavin, vitamin B6, folate, vitamin B12, betaine, selenium, Milk thistle extract, alpha-lipoic acid, N-Acetyl-L-Cysteine, resveratrol, epigallocatechin, curcumin, quercetin, Boswellia.



GUT PATHO	DGENS					
ODCANIEM	DETECTED		RESULT		COMMENTS	
ORGANISM	DETECTED	CURRENT	REF RANGE	PREVIOUS	COMMENTS	
Postovio	Clostridium difficile Toxin A	2.5e5	≤1e3	1e6	Consider broad-spectrum antimicrobial herbs including berberine, caprylic acid, garlic oil, oil of oregano, uva ursi, olive leaf extract.	
Bacteria	Plesiomonas shigelloides	7.5e4 ≤3e2		3.5e7	Consider broad-spectrum antimicrobial herbs including berberine, caprylic acid, garlic oil, oil of oregano, uva ursi, olive leaf extract.	
Antibiotic Resistance Genes	Helicobacter - Clarithromycin	DETECTED		DETECTED	Consider herbal formulas to eradicate or suppress H. pylori. Ingredients may include: deglycyrrhizinated licorice, mastic gum, methylmethionine sulfonium chloride, vitamin C, zinc carnosine, bismuth citrate, berberine, goldenseal, oil of oregano, grape extract, Chinese goldthread extract, yerba mansa extract. Rebuild healthy gastric mucosa by reducing stress and giving soothing and healing agents such as glutamine, aloe, DGL, and vitamin A.	

INFLAMMATION				
MARKER		RESULT		COMMENT
WAITCELL	CURRENT	REF RANGE	PREV	COMMENT
Calprotectin	424.4 mcg/g	≤50.0	417.7 mcg/g	Five polyphenols in particular have evidence of benefit in treating gut inflammation: resveratrol, epigallocatechin, curcumin, quercetin, and Boswellia. Sleep, diet, exercise and stress management should be evaluated. Be cautious with medications such as ibuprofen, acetaminophen, aspirin, especially in children.
Fecal lactoferrin	13.9 mcg/ml	≤6.4	13.9 mcg/ml	Elevated levels have been associated with IBD, diverticulitis or bacterial/parasitic infection leading to mucosal inflammation. Consider anti inflammatories such as fish oils, leukotriene inhibitors, N-acetyl glucosamine and balancing gut diversity with diet and probiotics.
Beta defensin 2	62.2 ng/mL	≤34.9	62.2 ng/mL	Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome.  Consider broad spectrum probiotics to improve gut diversity along with probiotic foods.
Lysozyme	126.6 ng/mL	≤575.0	126.6 ng/mL	
S100A12	26.5 mcg/ml	≤50.0	26.5 mcg/ml	
MMP 9	0.7 ng/mL	≤0.2	0.7 ng/mL	MMP9 is a major inflammatory marker of the gut. Consider supplements such as Curcumin, Coumarin, Resveratrol and Ginger root, which are anti inflammatory. Calcium supplementation has shown benefit in reducing epithelial permeability and inflammation in the intestine through reduced expression of MMP-9 in some studies.
Fecal Eosinophil Protein X	2.2 mcg/g	≤4.8	2.2 mcg/g	



MARKER		RESULT		COMMENT				
MARKER	CURRENT	REF RANGE	PREV	COMMENT				
Pancreatic elastase 1	190.6 mcg/g	≥200.0	153.5 mcg/g	Consider digestive support with betaine HCL. Consider pepsin, plant or pancreatic enzyme supplements, digestive herbs, bile salts, and taurine Micronutrient evaluation recommended, especially for fat soluble vitamins A, D, E, and K.  Consider eating six small meals per day. Chew thoroughly and relax at meal time. Stay well-hydrated. Avoid alcohol and smoking.				
Meat fiber	DETECTED		NOT DETECTED	Detection of undigested fibers is indicative of inadequate chewing, pancreatic or bile insufficiency. Bile acid levels, PE1 along with eating habits should be verified. Pancreatic enzyme, betaine HCL and cholagogues can be considered.				
Vegetable fiber	NOT DETECTED		DETECTED					
FAT MALABSORPTION								
Total Fecal Fat	24.7 mg/g	2.9~37.5	24.7 mg/g					
Total Fecal Triglycerides	6.1 mg/g	0.3~2.5	6.1 mg/g	High levels of fecal fat are suggestive of maldigestion or malabsorption. Consider cholagogues, betaine HCL, pancreatic enzyme supplementation to improve outcome. Phosphatidyl choline, serine and inositol can be considered when phospholipids are low.				
Long chain fatty acids	11.8 mg/g	0.9~28.1	11.8 mg/g					
Total Cholesterol	2.3 mg/g	0.5~5.3	2.3 mg/g					
Total Phospholipids	1.6 mg/g	0.3~6.4	1.6 mg/g					



GUT METABOLITE	S			
MARKER		RESULT		COMMENT
WARKER	CURRENT	REF RANGE	PREV	COMMENT
BILE ACID METABOLITES				
Cholic acid (CA)	0.25 %	≤0.36	0.28 %	
Chenodeoxycholic acid (CDCA)	0.31 %	≤1.25	1.24 %	
Deoxycholic acid (DCA)	32.90 %	24.25~75.84	19.93 %	
Lithocholic acid (LCA)	56.94 %	24.16~75.75	69.62 %	
LCA/DCA ratio	1.73	0.32~3.38	3.49	
SHORT CHAIN FATTY ACI	DS			
Acetate	68.2 %	60.2~72.7	62.0 %	
Butyrate	9.8 %	5.1~12.4	2.3 %	
Propionate	17.1 %	15.4~30.3	28.8 %	
Valerate	0.5 %	0.8~3.5	2.8 %	SCFA supplements are most commonly found as butyric acid salts. Herbal medicines that can affect SCFA levels include berberine, resistant starch. Best sources of resistant starches include: Green bananas (adding green banana flour to your daily routine works well. Raw plantains, Raw potato starch, Cooked and cooled rice, Legumes
Total Short chain fatty acids	10.2 micromol/g	45.4~210.1	98.1 micromol/g	SCFA supplements are most commonly found as butyric acid salts. Herbal medicines that can affect SCFA levels include berberine, resistant starch. Best sources of resistant starches include: Green bananas (adding green banana flour to your daily routine works well. Raw plantains, Raw potato starch, Cooked and cooled rice, Legumes



Other Markers						
MARKER		RESULT		COMMENT		
	CURRENT	REF RANGE	PREV	OOMINENT		
slgA	>3000.0 mcg/g	426.0~1450. 0	>3000.0 mcg/g	Elevated levels are indicative of immune upregulation in the gut. Causes could be due to food sensitivities, intestinal permeability or infections. Consider testing at peptide and protein levels for food sensitivities for higher sensitivity.		
ß-glucuronidase	1124 U/mL	≤2300	1088 U/mL			
Fecal Occult Blood	8.2 mcg/g	≤10.0	8.2 mcg/g			
рН	7.0	6.1~7.8	7.0			
Fecal Zonulin	341.9 ng/mL	25.1~160.8	341.9 ng/mL	Elevation indicative of intestinal permeability. Addressing gut dysbiosis and low diversity if any. Checking for food sensitivities at peptide and protein level recommended.		
Fecal Anti Gliadin	224.8 U/L	≤148.0	224.8 U/L	Fecal Anti Gliadin is a less sensitive marker of wheat sensitivity in comparison to serum antibodies to peptide fragments of wheat.  Individuals may consider running a Wheat Zoomer and/or following a gluten free diet.		





Gut Microbiome and Int	estinal Perme	eability				
GENUS/SPECIES	F	RELATIVE ABUNDANC	E	RATING	POTENTIAL ASSOCIATED RISK	
GENUS/SPECIES	CURRENT	REF RANGE	PREVIOUS 07/06/2021	HATING	POTENTIAL ASSOCIATED RISK	
Enterobacteriaceae -	6.6 ↔	≤20.0	10.9 ↔	****		
Akkermansia muciniphila	11.5 ↔	≥10.0	4.3 ↓	****	Intestinal permeability	
Bifidobacterium	29.4 ↔	≥10.0	21.3 ↔	***		
Propionibacterium	19.5 ↔	≥10.0	23.0 ↔	***		
Eubacterium	15.0 ↔	≥10.0	2.4 ↓	***	Lower SCFA production	
Lactobacillus	12.9 ↔	≥10.0	22.3 ↔	***		
Roseburia	19.6 ↔	≥10.0	19.3 ↔	***		
Eubacterium rectale	28.0 ↔	≥10.0	4.4 ↓	***		
Butyrivibrio	3.4 ↓	≥10.0	0.4 ↓	***	Lower butyrate production	
Faecalibacterium prausnitzii	15.0 ↔	≥10.0	15.0 ↔	***		
YOUR LEVELS OF PROBIOTIC	ORGANISMS					
Lactobacillus reuteri	23.4 ↔	≥10.0	9.9 ↓			
Lactobacillus rhamnosus	14.8 ↔	≥10.0	21.5 ↔			
Lactobacillus plantarum	16.7 ↔	≥10.0	28.0 ↔			
Streptococcus thermophilus	22.5 ↔	≥10.0	6.3 ↓			
Lactobacillus bulgaricus	17.6 ↔	≥10.0	16.8 ↔			
Lactobacillus acidophilus	11.5 ↔	≥10.0	29.5 ↔			
Bifidobacterium longum	21.0 ↔	≥10.0	29.8 ↔			

Based on clinical literature, the following probiotics and supplements maybe beneficial

Supplements: Arabinogalactan, Inulin.



Gut Microbiome and SIBO								
OENILO/ODEOIEO	F	RELATIVE ABUNDANC	E	DATINO	POTENTIAL ACCOUNTED DIOUS			
GENUS/SPECIES	CURRENT	REF RANGE	PREVIOUS 07/06/2021	RATING	POTENTIAL ASSOCIATED RISK*			
Streptococcus species	27.6 ↑	≤20.0	22.6 ↑	***				
Escherichia coli	3.1 ↔	≤20.0	8.3 ↔	***				
Staphylococcus species	15.2 ↔	≤20.0	30.0 ↑	***				
Micrococcus	15.5 ↔	≤20.0	20.8 ↑	***				
Acinetobacter _	19.5 ↔	≤20.0	4.2 ↔	***				
Bacteroides -	5.2 ↔	≤20.0	19.9 ↔	***	SIBO syndrome			
Clostridium	16.3 ↔	≤20.0	19.7 ↔	***				
Peptostreptococcus	3.9 ↔	≤20.0	3.5 ↔	***				
Enterococcus species	20.7 ↑	≤20.0	2.8 ↔	***				
Methanobrevibacter smithii	14.9 ↔	≤20.0	0.6 ↔	***				
YOUR LEVELS OF PROBIOTIC	ORGANISMS							
Lactobacillus casei	24.5 ↔	≥10.0	23.8 ↔					
Lactobacillus plantarum	16.7 ↔	≥10.0	28.0 ↔					

Based on clinical literature, the following probiotics and supplements maybe beneficial

Supplements: Berberine, Origanum vulgare, Wormwood oil, Lemon balm oil, Barberry root extract.



	R	ELATIVE ABUNDANC	E					
GENUS/SPECIES	CURRENT	REF RANGE	PREVIOUS 07/06/2021	RATING	POTENTIAL ASSOCIATED RISK*			
Collinsella	18.0 ↔	≤20.0	13.0 ↔	***	Atherosclerosis			
Lactobacillus ruminis	14.0 ↔	≤20.0	4.6 ↔	****				
Atopobium	26.1 ↑	≤20.0	16.7 ↔	****	Stroke			
Lactobacillus sakei	26.5 ↔	≥10.0	16.7 ↔	****				
Escherichia coli	3.1 ↔	≤20.0	8.3 ↔	****				
Enterobacter aerogenes	11.0 ↔	≤20.0	1.8 ↔	****				
Streptococcus species	27.6 ↑	≤20.0	22.6 ↑	****				
Solobacterium moorei	2.1 ↔	≤20.0	7.1 ↔	****				
Atopobium parvulum	0.4 ↔	≤20.0	19.7 ↔	****				
Roseburia intestinalis	6.4 ↓	≥10.0	26.1 ↔	****	O-ndi-vevilan di-			
Faecalibacterium prausnitzii	17.5 ↔	≥10.0	26.5 ↔	****	Cardiovascular disease			
Prevotella copri	17.1 ↔	≥10.0	15.3 ↔	****				
Alloprevotella -	25.3 ↔	≥10.0	16.6 ↔	****				
Catenibacterium	16.7 ↔	≥10.0	22.6 ↔	****				
Tyzzerella	15.6 ↔	≤20.0	15.5 ↔	****				
Tyzzerella 4	4.1 ↔	≤20.0	7.6 ↔	****				
YOUR LEVELS OF PROBIOTIC ORGANISMS								
Lactobac <mark>illus pl</mark> antarum	16.7 ↔	≥10.0	28.0 ↔					
Streptococcus thermophilus	22.5 ↔	≥10.0	6.3 ↓					

### Based on clinical literature, the following probiotics and supplements maybe beneficial

Supplements: Omega-3 fatty acids, vitamin D, isoflavone, Taurine, Chitin-Glucan.



Gut Bacteria and Autoimmune Health								
	R	ELATIVE ABUNDANC	E	D.4.TIN.10				
GENUS/SPECIES	CURRENT	REF RANGE	PREVIOUS 07/06/2021	RATING	POTENTIAL ASSOCIATED RISK*			
Porphyromonas gingivalis	5.0 ↔	≤20.0	4.4 ↔	***	Rheumatoid arthritis			
Lactobacillus	12.9 ↔	≥10.0	22.3 ↔	****				
Bifidobacterium	29.4 ↔	≥10.0	21.3 ↔	****				
Enterobacteriaceae -	6.6 ↔	≤20.0	10.9 ↔	***				
Staphylococcaceae	22.9 ↑	≤20.0	11.8 ↔	***	Celiac disease			
Staphylococcus epidermidis	14.3 ↔	≤20.0	3.2 ↔	***				
Staphylococcus pasteuri	13.9 ↔	≤20.0	23.3 ↑	***				
Coprococcus	11.0 ↔	≥10.0	0.3 ↓	***				
Akkermansia muciniphila	10.8 ↔	≥10.0	5.0 ↓	***	Psoriatic arthritis			
Pseudobutyrivibrio _	21.4 ↔	≥10.0	10.5 ↔	***				
Proteus mirabilis	5.9 ↔	≤20.0	22.8 ↑	**	Rheumatoid arthritis, Ankylosing spondylitis			
Enterococcus gallinarum	18.7 ↔	≤20.0	24.1 ↑	****	Autoimmunity			
Clostridia clusters XIVa	22.5 ↔	≥10.0	22.8 ↔	****				
Clostridia clusters IV	25.0 ↔	≥10.0	22.2 ↔	****	Inflammation, Allergy			
Clostridia clusters XVIII	23.1 ↔	≥10.0	26.0 ↔	****				
YOUR LEVELS OF PROBIOTIC ORGANISMS								
Lactobacillus acidophilus	11.5 ↔	≥10.0	29.5 ↔					
Lactobac <mark>illus c</mark> asei	24.5 ↔	≥10.0	23.8 ↔					
Bifidobacterium bifidum	12.7 ↔	≥10.0	29.2 ↔					

Based on clinical literature, the following probiotics and supplements maybe beneficial

Supplements: peptidase.



Gut Microbiome and Me	etabolic Healt	h			
	R	ELATIVE ABUNDANC	E	DATING	DOTENTIAL ACCOUNTS STORY
GENUS/SPECIES	CURRENT	REF RANGE	PREVIOUS 07/06/2021	RATING	POTENTIAL ASSOCIATED RISK*
Oscillospira -	29.3 ↑	≤20.0	23.4 ↑	****	Low BMI, Metabolic health
Christensenella minuta	7.5 ↔	≤20.0	8.8 ↔	****	Low Bivii, ivictabolic ricalui
Bacteroides caccae	13.0 ↔	≤20.0	1.6 ↔	****	
Clostridium hathewayi	29.2 ↑	≤20.0	3.6 ↔	****	
Clostridium ramosum	16.3 ↔	≤20.0	0.7 ↔	****	Dishetes Matabalia hashib
Clostridium symbiosum	25.1 ↑	≤20.0	4.0 ↔	****	Diabetes, Metabolic health
Eggerthella lenta	5.9 ↔	≤20.0	7.0 ↔	****	
Escherichia coli	3.1 ↔	≤20.0	8.3 ↔	****	
Bifidobacterium animalis	10.3 ↔	≥10.0	7.7 ↓	***	
Blautia hydrogenotorophica	0.1 ↔	≤20.0	20.4 ↑	**	Obesity, Metabolic health
Ruminococcus obeum	14.1 ↔	≤20.0	11.0 ↔	**	
Akkermansia muciniphila	11.5 ↔	≥10.0	4.3 ↓	****	Obesity, Diabetes, Metabolic healt
Methanobrevibacter smithii	14.9 ↔	≤20.0	0.6 ↔	**	IBS, Obesity, Metabolic health
Bifidobacterium adolescentis	15.7 ↔	≥10.0	29.5 ↔	***	Digestive insufficiency, Metabolic health
YOUR LEVELS OF PROBIOTIC	ORGANISMS				,
Lactobacillus paracasei	6.8 ↓	≥10.0	6.8 ↓		
Lactobacillus rhamnosus	14.8 ↔	≥10.0	21.5 ↔		
Lactobacillus acidophilus	11.5 ↔	≥10.0	29.5 ↔		
Lactobacillus casei	24.5 ↔	≥10.0	23.8 ↔		
Bifidobacterium animalis	10.3 ↔	≥10.0	7.7 ↓		

### Based on clinical literature, the following probiotics and supplements maybe beneficial

Probiotics: Lactobacillus paracasei.

Supplements: Omega-3 fatty acids, Whey protein concentrate, Watercress, Green tea catechins.



Gut Microbiome and Nut	trition					
OENI IO/ODEOIEO	R	ELATIVE ABUNDANC	E	DATINO	POTENTIAL ACCOUNTED DIOKS	
GENUS/SPECIES	CURRENT REF RANGE		PREVIOUS 07/06/2021	RATING	POTENTIAL ASSOCIATED RISK*	
Bifidobacterium	29.4 ↔	≥10.0	21.3 ↔	***		
Lactobacillus	12.9 ↔	≥10.0	22.3 ↔	****	Lower prodution of folate, Lower production of vitamin K, Lower	
Bacillus subtilis	27.4 ↔	≥10.0	15.3 ↔	****	production of riboflavin (vitamin B2) Lower production of cobalamin (vitamin B12)	
Propionibacterium freudenreichii	5.0 ↓	≥10.0	22.5 ↔	***		
Bifidobacterium animalis subspecies lactis	24.5 ↔	≥10.0	27.4 ↔	**	Oxalate degradation affected	
Lactobacillus animalis	13.2 ↔	≥10.0	10.4 ↔	**	examine adjudation and the	
Ruminococcus bromii	25.7 ↔	≥10.0	28.1 ↔	****	Digestive insufficiency	
Eubacterium rectale	28.0 ↔	≥10.0	4.4 ↓	***	Digestive insufficiency	
Roseburia	19.6 ↔	≥10.0	19.3 ↔	****		
Eubacterium rectale	28.0 ↔	≥10.0	4.4 ↓	****	Lower butyrate production	
Bifidobacterium	29.4 ↔	≥10.0	21.3 ↔	***		
YOUR LEVELS OF PROBIOTIC C	ORGANISMS					
Lactobacillus animalis	13.2 ↔	≥10.0	10.4 ↔			
Bifidobacterium animalis	10.3 ↔	≥10.0	7.7 ↓			

### Based on clinical literature, the following probiotics and supplements maybe beneficial

Supplements: protease, amyloglucosidase, beta-glucanase, alpha-galactoidase, lipase, amylases.



Gut Microbiome and Neurological Health						
GENUS/SPECIES	R	ELATIVE ABUNDANC	E	RATING	POTENTIAL ASSOCIATED RISK*	
GENOS/SFECIES	CURRENT	REF RANGE	PREVIOUS 07/06/2021	HATING		
Lactobacillaceae	17.8 ↔	≤20.0	29.6 ↑	****		
Bradyrhizobiaceae -	9.5 ↔	≤20.0	8.5 ↔	****	Parkinson's disease	
Clotridiales Incertae Sedis IV	27.4 ↑	≤20.0	24.6 ↑	****	T arkinsuits disease	
Enterobacteriaceae -	6.6 ↔	≤20.0	10.9 ↔	***		
Desulfovibrio	22.2 ↑	≤20.0	28.6 ↑	****		
Bacteroides vulgatus	26.7 ↑	≤20.0	16.9 ↔	****		
Bifidobacterium	29.4 ↔	≥10.0	21.3 ↔	****	Autism	
Prevotella -	6.9 ↓	≥10.0	20.4 ↔	***	Addistri	
Coprococcus	11.0 ↔	≥10.0	0.3 ↓	***		
Veillonellaceae -	23.2 ↔	≥10.0	22.6 ↔	***		
Bacteroidales -	3.3 ↔	≤20.0	10.3 ↔	***	Depression	
Lachnospiraceae	28.0 ↔	≥10.0	10.5 ↔	***	Боргозон	
Methanobrevibacter	22.6 ↑	≤20.0	14.9 ↔	***		
Butyricimonas -	18.8 ↔	≥10.0	29.4 ↔	***		
Pseudomonas	9.6 ↔	≤20.0	9.6 ↔	***		
Mycoplana -	8.0 ↔	≤20.0	3.5 ↔	***	Multiple sclerosis	
Haemophilus -	6.4 ↔	≤20.0	4.7 ↔	***		
Blautia	16.3 ↔	≤20.0	13.3 ↔	***		
Dorea	11.7 ↔	≤20.0	5.0 ↔	***		
Bifidobacterium	29.4 ↔	≥10.0	21.3 ↔	***	Alzheimer's disease.	
Bacteroides	5.2 ↔	≤20.0	19.9 ↔	***	, wellottion 3 disease.	
YOUR LEVELS OF PROBIOTIC	ORGANISMS					
_actobacillus acidophilus	11.5 ↔	≥10.0	29.5 ↔			
Lactobacillus casei	24.5 ↔	≥10.0	23.8 ↔			
_actobacillus fermentum	29.9 ↔	≥10.0	17.6 ↔			



FULL NAME: TEST2 PATIENT		ACCESSION	ID: <b>2108060411</b>
Bifidobacterium bifidum	12.7 ↔	≥10.0	29.2 ↔
Lactobacillus brevis	11.8 ↔	≥10.0	22.5 ↔
Bifidobacterium dentium	22.6 ↔	≥10.0	24.8 ↔
Streptococcus thermophilus	22.5 ↔	≥10.0	6.3 ↓
Lactobacillus bulgaricus	17.6 ↔	≥10.0	16.8 ↔
Streptococcus	25.8 ↔	≥10.0	13.7 ↔

### Based on clinical literature, the following probiotics and supplements maybe beneficial

Supplements: glycine, Pantothenic Acid, riboflavin, vitamin B6, folate, vitamin B12, betaine.





Gut Microbiome and Live	CFTTCardi						
GENUS/SPECIES	RELATIVE ABUNDANCE			RATING	POTENTIAL ASSOCIATED RISK		
	CURRENT	REF RANGE	PREVIOUS 07/06/2021				
Lactococcus	14.6 ↔	≥10.0	25.2 ↔	**			
Pediococcus	27.7 ↔	≥10.0	14.6 ↔	**	Alcohol-associated dysbiosis		
Lactobacillus	12.9 ↔	≥10.0	22.3 ↔	**	Alcohor-associated dysbiosis		
Leuconostoc	1.1 ↓	≥10.0	14.2 ↔	**			
Veillonella _	4.8 ↔	≤20.0	9.9 ↔	****			
Streptococcus species	27.6 ↑	≤20.0	22.6 ↑	****	Liver cirrhosis		
Clostridium	16.3 ↔	≤20.0	19.7 ↔	****			
Lachnospiraceae	28.0 ↔	≥10.0	10.5 ↔	***			
Ruminococcaceae	14.7 ↔	≥10.0	0.2 ↓	***			
Clostridiales Family XIV Incertae Sedis	12.2 ↔	≥10.0	15.1 ↔	***	Alcohol-related liver cirrhosis		
Enterobacteriaceae -	6.6 ↔	≤20.0	10.9 ↔	***			
Escherichia coli	3.1 ↔	≤20.0	8.3 ↔	***			
Streptococci	14.2 ↔	≤20.0	6.2 ↔	***			
Enterobacteria _	9.5 ↔	≤20.0	28.2 ↑	***	Alcoholic hepatitis		
Faecalibacterium prausnitzii	17.5 ↔	≥10.0	26.5 ↔	***			
Ruminococcus	17.6 ↔	≤20.0	5.1 ↔	***	Namelas halia atantah ayatitis		
Prevotella -	6.9 ↓	≥10.0	20.4 ↔	***	Nonalcoholic steatohepatitis		
Enterococcus	2.6 ↔	≤20.0	12.1 ↔	***			
Fusobacterium -	2.3 ↔	≤20.0	7.4 ↔	***			
Streptococcus species	27.6 ↑	≤20.0	22.6 ↑	****	Primary sclerosing cholangitis		
Veillonella	4.8 ↔	≤20.0	9.9 ↔	***			
YOUR LEVELS OF PROBIOTIC ORGANISMS							
Lactobacillus rhamnosus GG	29.1 ↔	≥10.0	10.2 ↔				
_actobacillus	12.9 ↔	≥10.0	22.3 ↔				
Bifidobacterium	29.4 ↔	≥10.0	21.3 ↔				



### Based on clinical literature, the following probiotics and supplements maybe beneficial

Supplements: selenium, Milk thistle extract, alpha-lipoic acid, N-Acetyl-L-Cysteine.



	R	ELATIVE ABUNDANC	E		
GENUS/SPECIES	CURRENT	REF RANGE	PREVIOUS 07/06/2021	RATING	POTENTIAL ASSOCIATED RISK*
Roseburia	19.6 ↔	≥10.0	19.3 ↔	****	
Phascolarctobacterim -	17.1 ↔	≤20.0	0.3 ↔	****	
Clostridium	16.3 ↔	≤20.0	19.7 ↔	****	
Ruminococcaceae	14.7 ↔	≥10.0	0.2 ↓	****	IBD
Faecalibacterium	12.8 ↔	≥10.0	17.8 ↔	****	
Desulfovibrio piger	20.5 ↑	≤20.0	18.4 ↔	****	
Faecalibacterium prausnitzii	17.5 ↔	≥10.0	26.5 ↔	***	
Akkermansia muciniphila	11.5 ↔	≥10.0	4.3 ↓	***	
Dialister invisus	17.8 ↔	≥10.0	29.2 ↔	***	
Faecalibacterium prausnitzii	17.5 ↔	≥10.0	26.5 ↔	***	
Bifidobacterium adolescentis	15.7 ↔	≥10.0	29.5 ↔	***	Crohn's disease
Ruminococcus gnavus	2.0 ↔	≤20.0	4.2 ↔	***	
Enterococcus	2.6 ↔	≤20.0	12.1 ↔	**	
Veillonella -	4.8 ↔	≤20.0	9.9 ↔	**	
YOUR LEVELS OF PROBIOTIC	ORGANISMS				, 
Saccharomyces boulardii	8.6 ↓	≥10.0	16.6 ↔		
Lactobacillus reuteri	23.4 ↔	≥10.0	9.9 ↓		
Lactobacillus plantarum	16.7 ↔	≥10.0	28.0 ↔		
Lactobacillus salivarius	4.6 ↓	≥10.0	22.6 ↔		
Bifidobacterium breve	27.2 ↔	≥10.0	16.8 ↔		
Bifidobacterium bifidum	12.7 ↔	≥10.0	29.2 ↔		
Lactobacillus acidophilus	11.5 ↔	≥10.0	29.5 ↔		
Escherichia coli Nissle	8.8 ↓	≥10.0	6.1 ↓		

Probiotics: Saccharomyces boulardii, Lactobacillus salivarius, Escherichia coli Nissle.



Supplements: resveratrol, epigallocatechin, curcumin, quercetin, Boswellia.





Gut Microbiome and IE		RELATIVE ABUNDANO	·E		
GENUS/SPECIES	CURRENT	REF RANGE	PREVIOUS 07/06/2021	RATING	POTENTIAL ASSOCIATED RISK*
Dorea	11.7 ↔	≤20.0	5.0 ↔	****	
Ruminococcus	17.6 ↔	≤20.0	5.1 ↔	****	
Clostridium	16.3 ↔	≤20.0	19.7 ↔	****	
Lactobacillus	12.9 ↔	≥10.0	22.3 ↔	****	lino.
Veillonella <sup>-</sup>	4.8 ↔	≤20.0	9.9 ↔	****	IBS
Bifidobacterium catenulatum	11.2 ↔	≥10.0	20.2 ↔	****	
Bifidobacterium	29.4 ↔	≥10.0	21.3 ↔	***	
Enterobacteriaceae -	6.6 ↔	≤20.0	10.9 ↔	***	
Roseburia	19.6 ↔	≥10.0	19.3 ↔	***	
Eubacterium rectale	28.0 ↔	≥10.0	4.4 ↓	***	Lower butyrate production
YOUR LEVELS OF PROBIOTIC	ORGANISMS				
Bacillus coagulans	12.2 ↔	≥10.0	25.2 ↔		
Bifidobacterium infantis	2.5 ↓	≥10.0	15.6 ↔		
Lactobacillus acidophilus	11.5 ↔	≥10.0	29.5 ↔		
Lactobacillus plantarum	16.7 ↔	≥10.0	28.0 ↔		
Lactobacillus rhamnosus	14.8 ↔	≥10.0	21.5 ↔		
Bifidobacterium breve	27.2 ↔	≥10.0	16.8 ↔		
Bifidobacterium lactis	28.7 ↔	≥10.0	18.1 ↔		
Bifidobacterium longum	21.0 ↔	≥10.0	29.8 ↔		
Streptococcus thermophilus	22.5 ↔	≥10.0	6.3 ↓		

Based on clinical literature, the following probiotics and supplements maybe beneficial

Probiotics: Bifidobacterium infantis.



Gut Microbiome and Hormones							
	RELATIVE ABUNDANCE						
GENUS/SPECIES	CURRENT	REF RANGE	PREVIOUS 07/06/2021	RATING	POTENTIAL ASSOCIATED RISK*		
ß-glucuronidase producing bacteria	9.5 ↔	≤20.0	17.7 ↔	****	Fatage was a take lieuw offe stad		
ß-galactosidase producing bacteria	10.0 ↔	≤20.0	2.8 ↔	****	Estrogen metabolism affected		





### **GUT PATHOGENS**

Bacteria				✓Detected Not	Detected
GENUS/SPECIES	CURRENT RESULT	RESULT	REF RANGE	PREVIOUS RESULT 07/06/2021	RESULT
Clostridium difficile Toxin A	2.5e5	✓	≤1e3	1e6	<b>✓</b>
Clostridium difficile Toxin B	<1e2		≤1e3	<1e2	
Campylobacter spp	<1e2		≤1e2	<1e2	_
Campylobacter jejuni	2e1	_	≤1e2	2e1	_
Campylobacter coli	<1e2	_	≤1e2	<1e2	_
Campylobacter upsaliensis	<1e2	_	≤1e2	<1e2	_
Plesiomonas shigelloides	7.5e4	<b>/</b>	≤3e2	3.5e7	✓
Vibrio (parahaemolyticus)	<3e3	\ _\ \	≤3e3	<3e3	_
Enteropathogenic E.coli (EPEC)	<1.5e3	1 -	≤1.5e3	<1.5e3	_
Enterotoxigenic E.coli (ETEC) Lt/St	<2e3	-	≤2e3	<2e3	_
E.coli O157	2e1	1 + 1	≤1e2	1e5	✓
Shiga-Like Toxin Producing E.coli (STEC) Stx1/Stx2	<1e2	_	≤1e2	<1e2	_
Shigella/EIEC	2e1	_	≤1e2	2e1	_
Helicobacter pylori	<1e2	_	≤1.5e4	<1e2	_
Listeria	<3e3	_	≤3e3	<3e3	_
Vibrio (cholerae)	<2e2	_	≤2e2	<2e2	_
Enteroaggregative E.coli (EAEC)	<1e2	_	≤1e2	<1e2	_
Klebsiella pneumoniae	<3.5e3	_	≤3.5e3	<3.5e3	_
Edwardsiella tarda	<4.5e3	_	≤4.5e3	<4.5e3	_
Yersinia enterocolitica	<2e4		≤2e4	<2e4	<u> </u>
Vibrio (vulnificus)	<1e4		≤1e4	<1e4	
Salmonella	<2e3	_	≤2e3	<2e3	_



Parasites - Protozoans				✓Detected Not	Detected
GENUS/SPECIES	CURRENT RESULT	RESULT	REF RANGE	PREVIOUS RESULT 07/06/2021	RESULT
Cryptosporidium	<1e2	_	≤1e2	<1e2	_
Entamoeba histolytica	<1e2	_	≤1e2	<1e2	_
Giardia lamblia	<4e2	_	≤4e2	<4e2	_
Cyclospora cayetanensis	<1.5e2	_	≤2e3	<1.5e2	
Chilomastix mesnili	<2e3	_	≤2e3	<2e3	_
Cyclospora spp.	<2.5e3	_	≤2.5e3	<2.5e3	_
Dientamoeba fragilis	<1e3	_	≤1e3	<1e3	_
Endolimax nana	<2e3	_	≤2e3	<2e3	_
Entamoeba coli	<2e3	_	≤2e3	<2e3	_
Pentatrichomonas hominis	<1e3		≤1e3	<1e3	_
Isospora belli	<1e3	1-1	≤1e3	<1e3	
Blastocystis hominis	<1e3	-	≤1e3	<1e3	_
Frichomonas hominis	<1e3		≤1e3	<1e3	



Parasites - Helminths	✓ Detected Not Detected				
GENUS/SPECIES	CURRENT RESULT	PREVIOUS RESULT 07/06/2021			
Strongyloides stercoralis	_	_			
Taenia solium	_	_			
Schistosoma	_				
Fasciola/Fasciolopsis	_	-			
Hymenolepis	_	-			
Dipylidium caninum		_			
Diphyllobothrium latum	_	_			
Enterobius vermicularis	-	_			
Mansonella		_			
Ancylostoma duodenale	_	_			
Ascaris lumbricoides	-	_			
Necator americanus	<u></u>	_			
Trichuris trichiura	_	_			
Taenia spp.	_	_			
Larval Nematode	_	_			



Virus				✓Detected Not	✓Detected Not Detected		
GENUS/SPECIES	CURRENT RESULT	RESULT	REF RANGE	PREVIOUS RESULT 07/06/2021	RESULT		
Adenovirus F40/41	<1e2	_	≤1e2	<1e2	_		
Rotavirus A	<3.1e2	_	≤3.1e2	<3.1e2			
Astrovirus	<1.2e3	_	≤1.2e3	<1.2e3	_		
Norovirus GI	<1e2	_	≤1e3	<1e2			
Norovirus GII	<1e2	_	≤1e3	<1e2			
Sapovirus I	<2.1e2	_	≤2.1e2	<2.1e2	_		
Sapovirus II	<2.1e2	_	≤2.1e2	<2.1e2	_		
Sapovirus V	<2.1e2		≤2.1e2	<2.1e2			
Sapovirus IV	<2.1e2	<u> </u>	≤2.1e2	<2.1e2			
cytomegalovirus	<1e3	A -\	≤1e3	<1e3	_		
pstein Barr virus	<1e3	1 - 1	≤1e3	<1e3	_		

Fungi				✓Detected Not	Detected
GENUS/SPECIES	CURRENT RESULT	RESULT	REF RANGE	PREVIOUS RESULT 07/06/2021	RESULT
Candida albicans	<1.1e2	_	≤1e2	<1.1e2	_
Candida spp.	2e1	_	≤1e2	2e1	_
Geotrichum spp.	<1.1e2	_	≤1e2	<1.1e2	_
Microsporidium spp.	<1.1e2		≤1e2	<1.1e2	_
Rodotorula spp.	<2.5e3	_	≤2.5e3	<2.5e3	_

Antibiotic Resistance Genes	✓Detected Not Detected			
GENUS/SPECIES	CURRENT RESULT	PREVIOUS RESULT 07/06/2021		
Helicobacter - Clarithromycin	✓	✓		
Helicobacter - Fluoroquinolones	_	_		
Universal Microbiota Resistance Genes - b-lactamase	_	_		
Universal Microbiota Resistance Genes - Fluoroquinolones	_	_		
Universal Microbiota Resistance Genes - Macrolides	_	_		
Universal Microbiota Resistance Genes - Vancomycin	_	_		



INFLAMMATION MARKERS			
CALPROTECTIN	CURRENT	REF RANGE	PREVIOUS
Calprotectin, a member of the S100 calcium- and zinc-binding protein family, is a protein released by a type of white blood cell called neutrophil. When there is inflammation in the gastrointestinal tract, neutrophils move to the area and release calprotectin, resulting in an increased level in the stool. The amount of calprotectin reflects the number of participating neutrophils in this inflammation. Calprotectin is most frequently used as part of the diagnostic evaluation of patients with suspected inflammatory bowel disease (IBD). For the individuals already diagnosed with IBD, it can be used to monitor the level of inflammation.	424.4 mcg/g	≤50.0	417.7 mcg/g
FECAL LACTOFERRIN			
Lactoferrin is a glycoprotein released by a type of white blood cell called neutrophil. Fecal lactoferrin is a biomarker of serious gastrointestinal inflammation. Gastrointestinal inflammation is associated with increased infiltration of activated neutrophils into the mucosa and increased release of lactoferrin into the gut. Clinical studies have shown that fecal lactoferrin levels of healthy persons are similar to irritable bowel syndrome (IBS) patients, but markedly increased in patients with active inflammatory bowel disease (IBD). Fecal lactoferrin levels are helpful in monitoring disease activity and efficacy of treatment for IBD.	13,9 mcg/ml	≤6.4	13.9 mcg/ml
BETA DEFENSIN 2			
Beta-defensin 2 is an antibiotic peptide locally regulated by inflammation in humans. It is produced by a number of epithelial cells and exhibits potent antimicrobial activity against Gram-negative bacteria and Candida, but not Gram-positive bacteria. It has been speculated that beta-defensin 2 may contribute to the infrequency of Gram-negative infections on skin and lung tissue.	62.2 ng/mL	≤34.9	62.2 ng/mL
LYSOZYME			
Fecal lysozyme concentration is an excellent parameter to gauge inflammatory activity in IBD patients.  Patients with IBS have been shown to have similar levels in comparison to healthy controls but this marker is highly elevated in IBD patients.	126.6 ng/mL	≤575.0	126.6 ng/mL
S100A12	1		
Fecal S100A12 is a novel noninvasive marker that has been shown to distinguish active IBD from healthy control subjects in certain populations. S100A12 levels were evenly distributed throughout fecal samples and were stable for 7 days when stored at room temperature. Fecal S100A12 was shown to be elevated in children with IBD compared with healthy control subjects, with levels closely correlated to disease activity and other serum inflammatory markers, particularly lower gut involvement.	26.5 mcg/ml	≤50.0	26.5 mcg/ml
MMP 9			
MMP-9 is an important marker of intestinal inflammation. It has been shown to be significantly increased in the stool of UC patients compared with healthy controls and patients with IBS, and was found to correlate with the clinical and endoscopic activity of UC.	0.7 ng/mL	≤0.2	0.7 ng/mL
FECAL EOSINOPHIL PROTEIN X			
Eosinophil Protein X (EPX) is a water-soluble protein that is found in eosinophils. EPX levels in stool are a marker of eosinophil activity in the gastrointestinal system. Fecal EPX abnormality is suggestive of food allergy, eosinophil-driven inflammation (caused by parasites). The test has been shown to have higher specificity and positive predictive value for detecting disease activity in inflammatory bowel disease compared to fecal calprotectin.	2.2 mcg/g	≤4.8	2.2 mcg/g



DIGESTIVE INSUFFICIENCY AND MALABSORPTION MARKE	RS		
PANCREATIC ELASTASE 1	CURRENT	REF RANGE	PREVIOUS
Pancreatic Elastase is an enzyme produced by exocrine tissue in the pancreas. Fecal pancreatic elastase is a non-invasive marker of exocrine pancreatic function. In the digestive tract, elastase is not broken down by other enzymes and is eventually eliminated from the body in the stool. Elastase can be detected and measured in the stool when a person's pancreas is functioning normally. The level in the stool is decreased when the exocrine tissues of the pancreas are not producing sufficient elastase and other digestive enzymes.	190.6 mcg/g	≥200.0	153.5 mcg
IEAT FIBER			
Presence of meat fibers is indicative of improper chewing or digestive insufficiency.	DETECTED		NOT DETECTE
EGETABLE FIBER			
Presence of vegetable fibers is indicative of improper chewing or digestive insufficiency.	NOT DETECTED		DETECTE
TAT MALABSORPTION			'
OTAL FECAL FAT			
This test measures the amount of fat in a stool sample. Excess fecal fat (termed steatorrhea) in stool is indicative of malabsorption disorder. The absorption of fat can be varied by production of bile in the gallbladder or liver, production of digestive enzymes in the pancreas, and normal functioning of the intestines. Decreased absorption of fat can be a sign of many different illnesses, including celiac disease, crohn's disease, cystic fibrosis, pancreatitis, etc.	24.7 mg/g	2.9~37.5	24.7 mg/(
OTAL FECAL TRIGLYCERIDES		'	'
Total triglyceride subfraction	6.1 mg/g	0.3~2.5	6.1 mg/g
ONG CHAIN FATTY ACIDS			
Total long chain fatty acids	11.8 mg/g	0.9~28.1	11.8 mg/g
OTAL CHOLESTEROL			
Total Cholestrol subfraction	2.3 mg/g	0.5~5.3	2.3 mg/g
OTAL PHOSPHOLIPIDS			
Total Phospholipid subfraction	1.6 mg/g	0.3~6.4	1.6 mg/g



# **GUT METABOLITES**

#### **BILE ACID METABOLITES**

Bile Acids are natural products of cholesterol synthesis that aid in the emulsification and absorption of dietary fats in the small intestine. Elevated total fecal bile acid is indicative of a diagnosis of bile acid malabsorption. Quantification of fecal bile acids aids in diagnosis for IBS and identification of patients with chronic diarrhea who may benefit from bile acid sequestrant therapy. There is a connection between the liver health, fecal bile acid concentrations, and gut microbiota composition. Bile acids have both direct antimicrobial effects on gut microbes and indirect effects through FXR-induced antimicrobial peptides. Cholic acid (CA), Chenodeoxycholic acid (CDCA), Deoxycholic acid (DCA), Lithocholic acid (LCA) are the major bile acids related to gut microbiome.

			7
CHOLIC ACID (CA)	CURRENT	REF RANGE	PREVIOUS
Cholic acid (CA) is synthesized in the liver from cholesterol. It undergoes enterohepatic circulation, in which its principal functions include induction of bile flow; feedback inhibition of bile acid synthesis; modulation of cholesterol synthesis; elimination of cholesterol; and the facilitation of dispersion and absorption of lipids and fat-soluble vitamins through the formation of micelles.	0.25 %	≤0.36	0.28 %
CHENODEOXYCHOLIC ACID (CDCA)			
Chenodeoxycholic acid (CDCA), also known as chenodiol, usually conjugates with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.	0.31 %	≤1.25	1.24 %
DEOXYCHOLIC ACID (DCA)			
Deoxycholic acid (DCA) is a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue.	32.90 %	24.25~75.84	19.93 %
LITHOCHOLIC ACID (LCA)			
Lithocholic acid (LCA) is a bile acid formed from chenodeoxycholate by bacterial action, usually conjugated with glycine or taurine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as cholagogue and choleretic. Chronically high levels of lithocholic acid are associated with several forms of cancer including colon cancer, pancreatic cancer, esophageal cancer, and many other GI cancers. High bile acid levels lead to the generation of reactive oxygen species and reactive nitrogen species, disruption of the cell membrane and mitochondria, induction of DNA damage, mutation and apoptosis, and the development of reduced apoptosis capability upon chronic exposure.	56.94 %	24.16~75.75	69.62 %
LCA/DCA RATIO			
LCA and DCA are secondary bile acids formed from CDCA and CA in the colon. The ratio when high or low has been found useful to check risk for several conditions such as colorectal cancer and gall stones.	1.73	0.32~3.38	3.49
SHORT CHAIN FATTY ACIDS			
ACETATE			
Acetic Acid can inhibit the accumulation of body fat and hepatic lipids without altering food consumption. It suppresses body fat accumulation by upregulating genes necessary for fatty-acid oxidation and mitochondrial processing. It has been found to have an inhibitory effect on the conversion of glucose to fatty acids in the liver. It has also been suggested as a promising compound for improving obesity and obesity-linked type 2 diabetes.	68.2 %	60.2~72.7	62.0 %
BUTYRATE			
Butyric Acid has been shown to enhance adaptive thermogenesis and fatty acid oxidation (burning of fat). It has also been shown to improve mitochondrial function, increase insulin sensitivity, and reduce fat production. Butyrate may assist treating and preventing diet induced insulin resistance by promoting energy production and enhancing mitochondrial function.	9.8 %	5.1~12.4	2.3 %
PROPIONATE			



FULL NAME:	TEST2 PATIENT	ACCESSION ID:	2108060411	DATE	OF SERVICE: 08-05	2021 18:08
of the microbial di preservatives. Abs enter the brain. Pr patients born with	gestion of carbohydrates. It is also sorbed propionic acid into the blood ropionic aciduria is a disease that c	of humans and other mammals as an an antifungal agent contained in many dicirculation may cross the blood brain omprises many various disorders. The err) is poor intellectual development pattations.	food barrier and outcome of	17.1 %	15.4~30.3	28.8 %
VALERATE						
important in chole neurotransmitter \(\gamma\) similar to its analoresulting in a decr that is elevated in levels of succinic	sterol metabolism. The structure of γ-aminobutyric acid (GABA), excep gue, valproic acid, which has been eased synthesis of succinic acid. S animals subjected to metabolic an acid are increased at the expense ritable bowel syndrome, ulcerative	nounts during fermentation of dietary filt valeric acid is very similar to that of the tor the terminal amino group. Valeric shown to increase the production of Guccinic acid is an inflammatory signalind inflammatory diseases and in high-fa of butyric acid. Valeric acid has also be colitis, Crohn's disease, colorectal cand	e inhibitory acid is GABA, ng molecule t diets the	0.5 %	0.8~3.5	2.8 %
TOTAL SHORT	CHAIN FATTY ACIDS					
cellulose, resistan important role in re diseases. Acetic a	at starch) by the bacteria in the gut. egulating metabolism in the gut and acid, propionic acid, and butyric aci t in the colon. A total of 13 SCFAs a	fermentation of insoluble fiber from diet These fatty acids have been shown to d are closely associated with gastrointed d are the most abundant, representing are quantified in stool to assist assessn	play an estinal 90-95% of	10.2 micromol/g	45.4~210.1	98.1 micromol/g



OTHER MARKERS			
SIGA	CURRENT	REF RANGE	PREVIOUS
Secretory IgA is the primary antibody that is protecting us from pathogens and toxins from penetrating mucosal surfaces. Its role is crucial in protecting the integrity of the intestinal epithelium. The antibody blocks the access to the epithelial receptors and traps pathogens and toxins in the mucus which are then excreated by peristaltic movements. SIgA has been identified to potentially neutralize virulence factors, modulate intestinal microbiota by Fab-dependent and -independent mechanisms, promote dendritic cell (DC) recruitement across the epithelial barrier and also down-regulate pro-inflammatory responses normally associated with the uptake of highly pathogenic bacteria and potentially allergenic antigens. Multiple cytokines, including IL-4, TGF- $\beta$ , IL-5, IL-6, IL-10 are instrumental in intestinal stimulating SIgA production. A subset of these cytokines, notably TGF- $\beta$ and IL-10, are also required for maintaining mucosal tolerance, thus establishing one of the many links between SIgA production, immunity and intestinal homeostasis.	>3000.0 mcg/g	426.0~1450.0	>3000.0 mcg/g
-GLUCURONIDASE			
Beta-glucuronidase is an enzyme induced by anaerobic bacteria. Many toxins, hormones, and drugs are excreted from the body after conjugation to a glucuronide molecule. Beta-glucuronidase can uncouple these conjugates, freeing these potential carcinogens in the bowel and increase cancer risk.	1124 U/mL	≤2300	1088 U/mL
ECAL OCCULT BLOOD			
Fecal occult blood testing (FOBT) checks stool samples for hidden (occult) blood loss from the mouth to the colon. A positive result indicates either upper gastrointestinal bleeding or lower gastrointestinal bleeding. The test does not directly detect colon cancer but is often used in clinical screening for that disease. It can also be used in early diagnosis of active occult blood loss in anemia or other gastrointestinal symptoms.	8.2 mcg/g	≤10.0	8.2 mcg/g
Н			
Fecal pH tests for acidity or alkalinity of stool samples. An acidic stool is suggestive of a digestive problem such as lactose intolerance, a pathogen such as E. coli or rotavirus, or overgrowth of the acid producing bacteria (such as lactic acid bacteria). A high alkaline pH rating is associated with the body's inability to create enough acid along with undigested food.	7.0	6.1~7.8	7.0
ECAL ZONULIN			
Fecal zonulin measurement may be advantageous, compared to serum zonulin when assessing intestinal permeability, as serum zonulin may constitute secretion not only from intestinal cells, but also from extraintestinal tissues such as the liver, heart and brain. Stool may therefore present a more appropriate specimen for analyzing only intestinal production of zonulin. Elevated fecal levels of zonulin have been associated with metabolic syndrome, obesity, and healthy cigarette smokers. High fecal zonulin levels in smokers irrespective of IBD point to the significant and undesirable up-regulation of gut permeability in cigarette smokers.	341.9 ng/mL	25.1~160.8	341.9 ng/m
ECAL A <mark>NTI G</mark> LIADIN			
Fecal anti-gliadin antibody tests for immune system reaction, IgA and IgG, to gluten in the diet. It enables direct and quantitative assessment of gluten exposure early after ingestion and could aid in the diagnosis and clinical management of nonresponsive CD and refractory CD.	224.8 U/L	≤148.0	224.8 U/L



# Risk and Limitations

Gut Zoomer testing is performed at Vibrant Genomics, a CLIA and CAP certified laboratory. However, laboratory error can occur, which might lead to incorrect results. Some of them may include sample or DNA mislabeling or contamination, operational error or failure to obtain data for certain genes. Vibrant's laboratory may need a second sample to complete the testing.

Vibrant Genomics has effective procedures in place to protect against technical and operational problems. However, such problems may still occur and examples include failure to obtain the Gut Zoomer abundance result for a specific species due to circumstances beyond Vibrant's control. Vibrant may re-test a sample in order to obtain these results but upon re-testing the results may still not be obtained. As with all medical laboratory testing, there is a small chance that the laboratory could report incorrect Gut Zoomer abundance results. A tested individual may wish to pursue further testing to verify any results.

Tested individuals should not change their diet, physical activity, or any medical treatments they are currently using based on the results without consulting their personal health care provider. These risk factors for Gut Zoomer are based on selected peer-reviewed scientific research findings as listed under references.

Tested individuals may find their experience is not consistent with Vibrant's selected peer reviewed scientific research findings of relative improvement for study groups. The science in this area is still developing and many personal health factors affect diet and health. Since subjects in the scientific studies referenced in this report may have had personal health and other factors different from those of tested individuals, results from these studies may not be representative of the results experienced by tested individuals. Further, some recommendations may or may not be attainable, depending on the tested individuals' physical ability or other personal health factors.

A limitation of this testing is that most scientific studies have been performed in Caucasian populations only. The interpretations and recommendations are done in the context of Caucasian studies, but the results may or may not be relevant to tested individuals of different or mixed ethnicities. Please note that pediatric ranges have not been established for these tests. Interference studies have not been established for individuals on immunosuppressive drugs.

Based on test results and other medical knowledge of the tested individual, health care providers might consider additional independent testing, or consult another health care provider or genetic counselor.